Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KGX101 Mono and Combo Therapy With Envafolimab in Advanced or Metastatic Solid Tumors
NCT07260305Phase 1Recruiting
- Sponsor
- KangaBio
- Start
- Nov 2024
- Primary completion
- Jan 2027
- Modality
- Cytokines & Interferons, Prodrugs/Conditional Activator Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of KGX101 in solid tumor (9 arms), sponsored by KangaBio. Primary endpoints: Adverse Events, Dose Limiting Toxicities and 2 more. Started Nov 2024; status: recruiting.
02
Drugs
KGX101
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07260305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07260305.